Jack Hellner "Where do we go to get real news these days?
"To judge by the current press coverage, it's not the press. Media outlets have dished up nothing but one-sided criticism of President Trump and have now ended up serving us just fake news.
"For example:
"In mid-January, the experts at the WHO repeated Chinese propaganda that the virus wouldn't spread from human to human, and the press repeated that as if it were fact. That was a lie. Instead of excoriating China for its duplicity, all they say is that President Trump should have known.
"Here's another:
"On Jan. 31, Trump implemented a travel ban from China. The mainstream press and its Democrat allies called that xenophobic, racist, and an overreaction. Now the critics say he reacted too slowly.
"Sometimes, the press goes full fake news, based on its urge to snipe at Trump.
"ABC loudly ran a false story on Wednesday, with no evidence, claiming that Trump was warned in November about the virus. On Thursday, the network started to bury it quietly." . . .
"Here's another:
"On Jan. 31, Trump implemented a travel ban from China. The mainstream press and its Democrat allies called that xenophobic, racist, and an overreaction. Now the critics say he reacted too slowly.
"Sometimes, the press goes full fake news, based on its urge to snipe at Trump.
"ABC loudly ran a false story on Wednesday, with no evidence, claiming that Trump was warned in November about the virus. On Thursday, the network started to bury it quietly." . . .
Not content with just that kind of fake news, the New York Times then decided to do a hit piece on Trump for a minuscule financial interest in a drug company, Sanofi, that happens to make a promising drug he cited as a potential COVID-19 treatment.
"According to National Review:
A New York Times story highlighting President Trump's "small personal financial interest" in a French pharmaceutical company that sells the brand-name version of hydroxychloroquine went viral Tuesday, as pundits and activists ignored the fact that Trump's holdings likely amount to less than $1,000 and that the company does not sell the drug in the U.S.
"This story was widely repeated by journalist puppets." . . .